Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...56789101112131415...208209»
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    PK/PD data, Journal:  Physiologically Based Pharmacokinetic Model for Fluzoparib Among Patients With Renal Impairment. (Pubmed Central) -  Apr 8, 2026   
    The simulations indicate that while no dose modification is needed for mild renal impairment, dose reduction is warranted for moderate and severe impairment to maintain equivalent systemic exposure. In the absence of clinical trial data, these findings provide a preliminary reference for dosing fluzoparib in cancer patients with renal impairment.
  • ||||||||||  AiTan (rivoceranib) / Elevar Therapeutics, Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date:  Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor (clinicaltrials.gov) -  Apr 8, 2026   
    P2,  N=48, Recruiting, 
    Epothilone A inhibits the activation of GEF-H1, thereby restoring the barrier function and reducing the mortality rate of sepsis. Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
  • ||||||||||  SHR-1819 / Jiangsu Hengrui Pharma
    Enrollment open, Trial initiation date:  A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis (clinicaltrials.gov) -  Apr 7, 2026   
    P3,  N=201, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Mar 2026
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Clinical, Journal:  The Effects of Remimazolam Tosylate on Postoperative Memory Function in Young and Middle-Aged Patients Undergoing Laparoscopic Surgery. (Pubmed Central) -  Apr 3, 2026   
    For young and middle-aged patients undergoing laparoscopic surgery, remimazolam reduces the incidence of early postoperative memory decline (within the first three days) and provides superior hemodynamic stability with a milder inflammatory response compared to propofol. However, no significant difference was observed in cognitive function at one month postoperatively, indicating that the benefits are primarily confined to the early recovery period.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, entecavir / Generic mfg.
    Journal:  Dalpiciclib induced hepatitis B virus reactivation leading to liver failure: a rare case report and review of the literature. (Pubmed Central) -  Apr 3, 2026   
    This case emphasizes the need for HBV screening and close monitoring of viral markers/liver function in asymptomatic HBV carriers receiving dalpiciclib, as early antiviral intervention prevents severe liver complications. It also highlights the importance of clinical pharmacist-led medication follow-up management for outpatients receiving targeted anticancer therapy to avoid oversight of comorbidities and associated prophylactic treatment.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / Elevar Therapeutics
    Enrollment closed, Trial completion date, Trial primary completion date:  Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas (clinicaltrials.gov) -  Apr 2, 2026   
    P1,  N=6, Active, not recruiting, 
    Trial primary completion date: Jul 2026 --> Jul 2028 Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Jun 2025
  • ||||||||||  Review, Journal, IO biomarker:  Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials. (Pubmed Central) -  Apr 1, 2026   
    The 2020-2025 period brought meaningful therapeutic advances for CTCL, including new FDA approvals, breakthrough designations, and emergence of cellular therapy. Future development should prioritize patient-reported outcomes as co-primary endpoints, prospective biomarker validation, and combination strategies with non-overlapping toxicity profiles.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Long-term survival in a patient with non-small cell lung cancer harboring KRAS G13C and TP53 co-mutations: case report and literature review. (Pubmed Central) -  Apr 1, 2026   
    The patient received first-line and maintenance therapy comprising carboplatin/pemetrexed, camrelizumab, and Endostar/bevacizumab...Our findings suggest that the combination of chemotherapy, immunotherapy, and anti-angiogenic agents may represent a viable therapeutic strategy for patients with KRAS G13C/TP53 co-mutated NSCLC. This case report suggests a potentially promising therapeutic strategy to improve long-term survival in this difficult-to-treat patient population.
  • ||||||||||  ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Journal:  Dose Recommendation of Remimazolam Tosilate for General Anesthesia in Children and Adolescents: Synergistic Combination of PopPK and PBPK Approaches. (Pubmed Central) -  Mar 28, 2026   
    The model-informed dosing regimens have received regulatory approval from the Center for Drug Evaluation (CDE) in China and are currently being evaluated in an ongoing clinical trial. The integrated PopPK-PBPK approach supports evidence-based dosing recommendations of remimazolam for general anesthesia in children and adolescents aged 3-18 years and provides a reference for dose selection in future clinical studies.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Retrospective data, Journal:  Efficacy and Safety of Dalpiciclib in HR-Positive Advanced Breast Cancer: A Two-Center Retrospective Study. (Pubmed Central) -  Mar 28, 2026   
    Dalpiciclib combined with endocrine therapy is associated with favorable efficacy and safety in real-world settings, with early-line treatment and lower tumor proliferative activity associated with better outcomes. While findings suggest potential for clinical application, further large-scale prospective studies are needed to validate its effectiveness in different patient subgroups and optimize treatment strategies.
  • ||||||||||  Review, Journal:  Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors. (Pubmed Central) -  Mar 28, 2026   
    Novel CDK4/6 inhibitors including dalpiciclib and next-generation agents are expanding therapeutic options, while combination strategies incorporating CDK7 inhibition represent future therapeutic frontiers. The evolving landscape of HER2+/HR+ breast cancer treatment increasingly emphasizes precision medicine approaches that leverage cell cycle control mechanisms to overcome resistance and improve patient outcomes across all disease stages.
  • ||||||||||  AiTan (rivoceranib) / Elevar Therapeutics
    Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker:  The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights. (Pubmed Central) -  Mar 26, 2026   
    Future priorities: accelerate late-phase trials for promising regimens, reduce global disparities via regional consortia, integrate precision biomarkers for patient stratification, and translate TME insights into trials. This analysis highlights the need to shift from conventional chemotherapy optimization to precision-driven, globally equitable strategies to improve outcomes for high-risk osteosarcoma patients.
  • ||||||||||  Review, Journal:  Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management. (Pubmed Central) -  Mar 25, 2026   
    The three approved agents - romiplostim, eltrombopag, and avatrombopag - all stimulate the c-Mpl receptor but differ in their molecular interactions, pharmacokinetics, and potential immunomodulatory properties...TPO-RAs now represent a cornerstone of chronic ITP management and are expected to see broader use as growing evidence supports earlier and more individualized treatment strategies. Future progress will rely on personalized therapeutic strategies, informed monitoring, and AI-driven predictive tools that together may enhance remission durability and long-term clinical outcomes.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Yidafan (ivonescimab) / Summit Therapeutics
    New P2 trial:  SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC (clinicaltrials.gov) -  Mar 24, 2026   
    P2,  N=30, Not yet recruiting, 
  • ||||||||||  SHR-2173 / Jiangsu Hengrui Pharma
    Trial initiation date:  A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) -  Mar 21, 2026   
    P2,  N=248, Not yet recruiting, 
    Trial primary completion date: Feb 2026 --> Feb 2027 Initiation date: Dec 2025 --> Mar 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, AiRuiKa (camrelizumab) / Elevar Therapeutics
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma. (Pubmed Central) -  Mar 20, 2026   
    However, primary resistance remains a challenge, driven by mechanisms such as M2 macrophage suppression and cancer stem cell escape. Future efforts should focus on multi-omics biomarker integration, optimizing de-escalation strategies for responders, and targeting resistant pathways within the tumor microenvironment to establish a new paradigm of chronic disease management for ESCC.
  • ||||||||||  Comparative efficacy and prognostic analysis of different targeted-immunotherapy regimens in advanced hepatocellular carcinoma (Poster Area - Hall 7) -  Mar 18, 2026 - Abstract #EASL2026EASL_2179;    
    In this real-world cohort, first-line lenvatinib-, bevacizumab-, and donafenib-based PD-1 inhibitor combinations demonstrated comparable survival outcomes in advanced HCC. Achieving an objective response and successful conversion to curative surgery were independent favorable prognostic factors, highlighting the critical importance of tumor downstaging and surgical eligibility in optimizing long-term survival.